Lipids & metabolic liver disease
A Population-Based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia
Authors' conclusion
Both in the general population and in at-risk individuals with MAFLD, MHF was related with poorer clinical outcomes.
Study context
- Population
- General population (NHANES) and patients with biopsy-proven MAFLD (PERSONS cohort)
- Exposure
- Metabolic hyperferritinemia (MHF) vs non-MHF
- Outcome
- Clinical outcomes, including all-cause death, comorbidities, and liver histology
Methodological detailspopulation-based (NHANES) and clinical biopsy cohort (PERSONS), adjusted models
- Population-based (NHANES) and clinical biopsy cohort (PERSONS)
- Adjusted models
Main finding
As reported in the abstract
Clinical outcomes in NHANES, MHF vs non-MHF with MD
- MHF vs Non-MHF with MD: P = 0.036
- MHF vs Non-MHF with MD: P = 0.001
- MHF vs Non-MHF with MD: P = 0.013
- MHF vs Non-MHF with MD: P = 0.122
- MHF vs Non-MHF with MD: P = 0.029
- Adjusted models
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| NHANES, MHF vs non-MHF without MDMHF vs Non-MHF without MD · mortality | P < 0.001 |
| NHANES, MHF vs non-MHF without MDMHF vs Non-MHF without MD · elevated UACR | P < 0.001 |
| NHANES, MHF vs non-MHF without MDMHF vs Non-MHF without MD · CVD | P = 0.028 |
| NHANES, MHF vs non-MHF without MDMHF vs Non-MHF without MD · sarcopenia | P < 0.001 |
| Liver histology, PERSONS cohort (biopsy-proven MAFLD), MHF vs non-MHFMHF vs Non-MHF · more advanced steatosis grades | P < 0.001 |
| Liver histology, PERSONS cohort (biopsy-proven MAFLD), MHF vs non-MHFMHF vs Non-MHF · lobular inflammation | P < 0.001 |
| Liver histology, PERSONS cohort (biopsy-proven MAFLD), MHF vs non-MHFMHF vs Non-MHF · advanced fibrosis | P = 0.017 |
| Liver histology, PERSONS cohort (biopsy-proven MAFLD), MHF vs non-MHFMHF vs Non-MHF · more severe hepatocellular iron deposition | P < 0.001 |
Original publication
A Population-Based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia. J Clin Endocrinol Metab. Published 20 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →